Our latest Sifted report — available exclusively for Pro members — features the top entrepreneurs, investors and modern-day shamans vying to take the small but fast-growing world of psychedelics mainstream in mental health treatment.
If clinical trials go well, drugs like LSD and psilocybin could begin to replace antidepressants and other established treatments. Whoever patents these new treatments will be well placed to win a big chunk of the global $380bn mental healthcare market. Will the findings of a growing cohort of psychedelics startups be suitably mind-changing? This report is exclusively for Sifted Pro members. Get in touch with the team today with code PSYCHREPORT10 for an exclusive discount! |